Table 1.

Summary of main points and recommendations for clinical practice

1. GV can be more readily assessed in clinical practice as a result of the increasing uptake of continuous and intermittently viewed glucose monitoring

2. SD, CoV, AGP and TIR are commonly used to assess GV in clinical practice

3. GV is a more clinically relevant marker of daily glucose control and hypoglycaemia risk than HbA1c

4. We recommend that clinicians interpret glucose data in the context of mean glucose, SD, CoV, AGP and TIR; in T1DM, these often provide more meaningful data to inform therapeutic decisions than HbA1c

5. Achieving widespread recognition of GV as a key metric of therapeutic success will require the following: Improved access to CGM for individuals living with diabetes Standardized reporting of GV across all product reporting systems Further studies investigating the relationship between CGM‐derived GV with short‐ and long‐term health outcomes

6. Modern technologies (CGM, CSII, closed‐loop) and adjunctive agents (metformin, SGLT2) provide exciting opportunities to explore the impact of GV as a primary outcome of interest

Abbreviations: AGP, ambulatory glucose profile; CGM, continuous glucose monitoring; CSII, continuous subcutaneous insulin infusion; GV, glycaemic variability; iCGM, integrated continuous glucose monitoring; SD, standard deviation; SGLT2, sodium‐glucose co‐transporter 2; T1DM, type 1 diabetes mellitus; TIR, time in range.